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Objectives. To assess prospectively the early time course of Transforming Growth Factor beta-1 (TGFb-1), basic Fibroblast
Growth Factor (bFGF) and Tumor Necrosis Factor alpha (TNFa) as possible contributors to restenosis development after
angioplasty.
Design. Prospective Study.
Methods. The levels of the soluble forms of these factors in the early response to Percutaneous Transluminal Angioplasty
(PTA) in the arteries of the lower limb were prospectively assessed. 32 patients with peripheral arterial occlusive disease
(PAOD), presenting with intermittent claudication (Fontaine stage IIb) were scheduled for angioplasty treatment. Serum
levels of TGFb-1, TNFa and bFGF were assessed before intervention, 15 and 60 minutes after, 24 hours after as well as
2 and 4 weeks after intervention. We compared the distribution patterns between patients treated with balloon angioplasty
and patients who required secondary stent implantation. Endpoint was the development of restenosis within 6 months after
interventional treatment, defined as a lumen diameter reduction of more than 50% by ultrasound measurement compared
to the result after PTA.
Results. The patients who later developed restenosis had significantly higher levels of TGFb-1 at 15 minutes, 24 hours and
2 weeks after PTA (p< 0.05). TNFa and bFGF were only detected in a few patients and no significant change of serum
levels was observed.
Conclusion. The results demonstrate a possible role of TGFb-1 in the formation of restenosis after PTA.
Keywords: Angioplasty; Restenosis; Peripheral arterial occlusive disease; Growth factors; Transforming Growth Factor beta.Introduction
The long term benefit of percutaneous transluminal an-
gioplasty (PTA) is severely limited by the development
of restenosis. The restenosis rate varies between spe-
cific vessels, the extent of the disease and the type of
endovascular treatment. Overall, restenosis occurs in
approximately 30e40% after balloon dilations within
3e6 months.1 Also primary stenting of peripheral ves-
sels did not improve the patency rate to a satisfying
level.2 Arterial remodelling, neointimal hyperplasia,
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at the site of vascular injury are discussed to be reasons
for restenosis.3
Several growth factors have been identified and
considered to play a key role in the mechanisms of
restenosis formation.4e6
Histopathological studies of experimental angio-
plasty in animal models showed that the angioplasty
procedure severely damages the endothelium and
subendothelial structures. Endovascular ultrasound
studies as well as post-mortem histopathological anal-
ysis revealed that similar damage to the arterial wall
occurs after angioplasty in humans.7,8 In the animal
model the angioplasty-induced trauma leads to a local
activation of inflammatory and haemostatic mecha-
nisms which can initiate the production of signallingerved.
36 M. Wildgruber et al.mediators such as Transforming Growth Factor b-1
(TGFb-1), Tumor Necrosis Factor a (TNFa) and basic
Fibroblast Growth Factor (bFGF). These factors can
be identified in animal tissue specimens obtained
after arterial injury.4,6,9e12
TGFb-1, a potent regulator of wound healing and
scar formation is important in the response to balloon
induced arterial injury.4 TGFb-1 is mainly produced
by smooth muscle cells (SMC) which are stimulated
by the balloon induced trauma.5 That subsequently
leads to increased cellular proliferation, extracellular
matrix production in the arterial wall and transforma-
tion of vascular fibroblasts to myofibroblasts.13e15
TNFa is another important mediator in the develop-
ment of restenotic lesions.6 It was originally regarded
exclusively as a product of activated macrophages.
However, in several studies, SMCshave been identified
as an alternative source of this cytokine.16 TNFa is
expressed in the media as early as 6 hours after balloon
catheter injury. TheTNFa expression leads to a stimula-
tory effect on SMC migration into the intima.9
bFGF is synthesized by the arterial wall and acts as
a potent mitogen for endothelial cells and SMCs.17
Blocking the bFGF pathways with a neutralizing anti-
body prior to catheterization leads to an inhibition of
SMC proliferation demonstrating that bFGF is one of
the major mitogens promoting the growth of vascular
SMC following denuding injury.18
Despite these data knowledge about angioplasty-
induced arterial trauma and restenosis development
in humans is still incomplete.
The aim of our study was to assess prospectively
the levels of TGFb-1, TNFa and bFGF in their soluble
forms detected in the serum during the early phase
after transluminal balloon angioplasty and additional
stent placement. These factors were shown to contrib-
ute to restenosis formation in animal models and
in-vitro studies and inhibiting their mediated path-
ways by selective antibodies or gene transfer was
proven to reduce restenosis rate. We expected PTA
to increase the expression and release of soluble
growth factors into the blood. Focusing on restenosis,
we intended to gain a better understanding of the
complex pathophysiology of angioplasty induced ves-
sel trauma, its consequences, and thus the delayed
failure of angioplasty procedures.
Methods
Patients
Thirty-two patients (17 men, 15 women, mean age
67.3 8.1 years) with PAOD and indication for
Eur J Vasc Endovasc Surg Vol 34, July 2007interventional treatment were prospectively assessed.
All patients presented with symptoms of intermittent
claudication (Fontaine stage IIb). The severity of
PAODwasassessedbymeasurement of ankle-brachial-
index (ABI) at rest and treadmill test and hemody-
namic and morphologic severity of the lesions were
assessed non-invasively by duplex sonography (Sys-
tem Five, Vingmed Sounds A/S, Horten, Norway)
and during angiography. Patient characteristics are
listed in Tables 1 and 2.
The study was carried out according to the guide-
lines of the World Medical Association Declaration
of Helsinki. All patients gave written informed
consent and the study was approved by the Internal
Review Board Committee of the Interdisciplinary
Centre for Vascular Diseases of the Technical Univer-
sity of Munich. Patients with documented malignant
diseases and/or vasculitis were excluded. All medica-
tions for concomitant diseases except coumarin
derivatives were continued during the time of study
participation. Medication status as well as recorded
risk factors are shown in Tables 1 and 2.
Lesions
Seventeen patients (53.1%) had lesions in the iliac
artery, 13 patients (40.6%) in the superficial femoral
artery and 2 patients (6.3%) in the popliteal artery.
The average lumen narrowing was 83.9 12.2%, the
average length of stenosis 2.0 1.3 cm, graded on
angiographic profile by the performing radiologist.
Detailed descriptions of lesions are shown in Table 3,
procedural characteristics in Table 4.
Angiography and angioplasty procedures
All patients received diagnostic digital subtraction
angiography of the lower limbs prior to interventional
treatment. A non-ionic contrast material Iomeprol
(Imeron 300, Altana Pharma GmbH, Konstanz,
Germany) was used, 182.0 68.3 ml per patient.
Balloon angioplasty was performed in 22 patients
(68.8%) in 10 patients (31.2%) secondary stenting
had to be performed due to residual stenosis greater
than 30% or flow limiting elastic recoil, dissection or
intimal flap. As stenting devices, self expanding
nitinol stents (Xpert, Abbott Vascular Devices,
Abbott Park, Illinois, USA) with diameters from 5 to
8 mm and lengths from 20 to 60 mm were used.
After the procedure, 18 patients (56.3%) had a
three-vessel-runoff, 12 patients (37.5%) had a two-
vessel-runoff and only 2 patients (6.2%) had a one-
vessel-runoff.
37Course of Growth Factors in Restenosis after PTATable 1. Patient characteristics
Balloon n¼ 22 Stenting n¼ 10 Total n¼ 32 P value
Age (in years)* 69.5 8.58 62.3 4.6 67.25 8.09 0.019
BMI (in kg/m2)* 24.54 4.01 25.47 2.21 24.83 3.48 0.496
Sexy 0.819
Male 12(54.5) 5(50) 17(53.1)
Female 10(45.5) 5(50) 15(46.9)
Risk factorsy
Hypertension 18(81.8) 9(90) 27(84.4) 0.569
Hypercholesterolemia 13(59.1) 7(70) 20(62.5) 0.483
Adipositas 2(9.1) 0(0) 2(6.3) 0.341
Diabetes 0.544
IDDM 2(9.1) 0(0) 2(6.3)
NIDDM 3(13.6) 1(10) 4(12.5)
Tobacco use 18(81.8) 9(90) 27(84.4) 0.569
Other arteriosclerotic diseasesy
Coronary artery disease 3(13.6) 3(30) 6(18.8) 0.287
Carotid disease 5(22.7) 1(10) 6(18.8) 0.409
Plasma levels*
CRP 0.76 0.53 0.81 0.63 0.77 0.54 0.996
Fibrinogen 413.8 157.7 353.5 76.2 387.0 117.8 0.671
Ankle-brachial index*
ABI before intervention 0.66 0.23 0.62 0.28 0.65 0.24 0.949
ABI at discharge 0.86 0.2 0.89 0.28 0.88 0.22 0.831
Medicationy
Thrombocyte inhibitors 18(81.8) 9(90) 27(84.4) 0.569
Vasodilators 8(36.4) 5(50) 13(40.6) 0.483
Lipid lowering agents 10(45.5) 4(40) 14(43.8) 0.782
b-blockers 10(45.5) 5(50) 15(46.9) 0.819
ACE inhibitors 9(40.9) 7(70) 16(50.0) 0.136
* Data are mean SD.
y Data are numbers of patients unless otherwise indicated, number in parentheses are percentages P value obtained with Student’s t-Test.Angiography and angioplasty procedures were
carried by two experienced interventional radiologists
(W.W., H.B.) according to established and accepted
technique. All interventional procedures were tech-
nically successful, 1 patient required surgical revision
due to bleeding at the puncture site. A bolus of
3000e5000 I.U. unfractionated heparin was given
intra-arterially as antithrombotic prophylaxis. After
PTA acetylsalicylate acid 100 mg/day and clopidogrel
75 mg/day were given as standard treatment as
recommended,19,20 acetylsalicylate acid for at least
six months, clopidogrel for at least three months.
Further characteristics of the performed procedures
are listed in Table 4.
Laboratory tests
Fasting venous blood samples for laboratory testing
were drawn in pyrogen-free tubes on the day before
the interventional procedure (between 10 and 12 am),
15 and 60 minutes after the last inflation of the angio-
plasty balloon or the placement of the stent, 24 hours
after the intervention, as well as 2 and 4 weeks after
the intervention. Blood samples were allowed to clotfor 1e2 h at room temperature before being centrifuged
at 2500 r.p.m for 5 minutes. The obtained platelet-
poor serum was stored at 70 C until laboratory test-
ing. The method of reducing the platelet count to a
minimum, which would otherwise affect TGFb-1
levels, has been previously described.21 The time range
from sample collection until freezing was a maximum
of 2 hours. After thawing, all serum samples where
centrifuged again (13000 r.p.m., 4 C, 10 minutes)
before immounoassays were performed. Concerning
TGFb-1, sample extraction to release TGFb-1 from
latent complexes was performed by using extracting
solution provided by the manufacturer.
Laboratory testing for the soluble forms of TGFb-1,
TNFa and bFGF were performed using standardised
enzyme-linked immunosorbent assay (ELISA) kits
(BioSource International, Camarillo, California). The
TGFb ELISA was specific for the isoform 1 of TGFb
(TGFb-1). Standardization was done using recom-
binant growth factors provided with the kits. An
ELISA-reader (Dynatech Laboratories, USA) set to
450 nm with wave length correction set to 620 nm
determined the optical density. The minimum detect-
able levels were 15.6 pg/ml for TGFb-1, 1.7 pg/ml for
Eur J Vasc Endovasc Surg Vol 34, July 2007
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No restenosis n¼ 22 Restenosis n¼ 10 Total n¼ 32 P value
Age (in years)* 68.32 9.23 64.9 4.98 67.25 8.22 0.283
BMI (in kg/m2)* 24.1 3.29 26.43 3.71 24.83 3.54 0.085
Sexy 0.819
Male 12(54.5) 5(50) 17(53.1)
Female 10(45.5) 5(50) 15(46.9)
Risk factorsy
Hypertension 18(81.8) 9(90) 27(84.4) 0.569
Hypercholesterolemia 11(50) 9(90) 20(62.5) 0.031
Adipositas 1(4.5) 1(10) 2(6.3) 0.569
Diabetes 0.115
IDDM 0(0) 2(20) 2(6.3)
NIDDM 2(9.1) 2(20) 4(12.5)
Tobacco use 20(90.9) 7(70) 27(84.4) 0.141
Other arteriosclerotic diseasesy
Coronary artery disease 4(18.2) 2(20) 6(18.8) 0.907
Carotid disease 3(13.6) 3(30) 6(18.8) 0.287
Plasma levels*
CRP 0.86 0.63 0.6 0.29 0.77 0.55 0.424
Fibrinogen 351.7 124.2 457.7 112.5 387 124.9 0.243
Ankle-brachial index*
ABI before intervention 0.7 0.178 0.54 0.33 0.65 0.24 0.301
ABI at discharge 0.91 0.14 0.78 0.33 0.87 0.22 0.338
Medicationy
Thrombocyte inhibitors 18(81.8) 9(90) 27(84.4) 0.569
Vasodilators 6(27.3) 7(70) 13(40.6) 0.022
Lipid lowering agents 7(31.8) 7(70) 14(43.2) 0.045
b-blockers 8(36.4) 7(70) 15(46.9) 0.082
ACE inhibitors 9(40.9) 7(70) 16(50) 0.136
* Date are mean SD.
y Data are numers of patients unless otherwise indicated, number in parentheses are percentages P value obtained with Student’s t-Test.TNFa and 7 pg/ml for bFGF. The vascular surgeons
who performed the follow-up ultrasound studies as
well as the performing radiologists were blind to the
lab results. Additionally the laboratory technician
who performed the immunological assays was blind
to the treatment groups.
Follow up
Clinical examination and ABI were performed on the
day before the interventional procedure, on the day of
discharge, two and four weeks as well as six months
after intervention. Endpoint of the studywas the devel-
opment of restenosis within 6 months defined as a
reduction in sonographic diameter greater than 50%
at the site of PTA. Before the intervention all lesions
were scanned and graded by duplex sonography.
Lumen diameters were measured on angiographic
profile immediately after angioplasty and verified
with duplex sonography. After sixmonths all PTA sites
were scanned with duplex sonography and lumen
diameters of the treated segments were measured and
compared to the result after PTA, according to the
Ja¨ger/Strandness classification.22 This technique has
Eur J Vasc Endovasc Surg Vol 34, July 2007been widely accepted and a sensitivity of 92% and
specifity of 98% in grading lesions from the iliac to the
popliteal segment have been reported.23,24 Restenosis
was therefore defined morphologically and haemody-
namically. All duplex examinations were performed
by two experienced vascular surgeons (H.P., W.O.).
No follow-up angiographies were performed.
Statistics
Results are given as mean standard deviation. Two-
group comparisons of patient characteristics were
done with the Student’s t-Test. Three-group compari-
sons of patient characteristics were done using Fisher’s
Exact Test. Comparisons between groups of the growth
factor levels were computed with 2-factor analysis of
variance (1 between, 1 within). To analyse a possible
influence of patient risk factors on the marker levels
a correlation model (Pearson’s correlation) between
the risk factors and mean serum levels was computed.
A probability level of p< 0.05 was considered to be
statistically significant. All analyses were performed
with SPSS 12.0 (SPSS INC., Chicago, Illinois).
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Ten of the patients treatedwith either angioplasty alone
or balloon angioplasty followed by stenting (31%)
developed restenosis in the first 6 months following
PTA. Table 2 showspatient characteristics of this group.
Table 3. Angiographic characteristics
Ballon
n¼ 22
Stenting
n¼ 10
Total
n¼ 32
P value
Location of obstruction*
Iliac artery 10(45.5) 7(70) 17(53.1) 0.293z
TASC Classification
TASC A 9(90) 2(28.6) 11(64.7)
TASC B 1(10) 5(71.4) 6(35.3)
TASC C 0(0) 0(0) 0(0)
TASC D 0(0) 0(0) 0(0)
Femoral artery 10(45.5) 3(30) 13(40.6) 0.293z
TASC Classification
TASC A 8(80) 2(66.7) 10(76.9)
TASC B 2(20) 0(0) 2(15.4)
TASC C 0(0) 1(33.3) 1(7.7)
TASC D 0(0) 0(0) 0(0)
Popliteal artery 2(9.0) 0(0) 2(6.3) 0.293z
TASC Classification
TASC A 1(50.0) 0(0) 1(50.0)
TASC B 1(50.0) 0(0) 1(50.0)
TASC C 0(0) 0(0) 0(0)
TASC D 0(0) 0(0) 0(0)
Mono-/bilateral stenosis* 0.426x
Monolateral 10(45.5) 3(30) 13(40.6)
Bilateral 12(54.5) 7(70) 19(59.4)
Degree of obstructiony
lumen obstruction
(in %)
81.5 13.77 90 4.63 83.93 12.20 0.231x
length of stenosis
(in cm)
1.79 0.97 2.63 1.90 2.02 1.29 0.222x
TASC¼ Trans Atlantic Society Consensus.
* Data are numbers of patients unless otherwise indicated, num-
ber in parentheses are percentages within group.
y Data are mean SD.
z P Value obtained with Fisher’s Exact Test.
x P Value obtained with Student’s t-Test.Patients who developed restenosis sufferedmore often
from hypercholesterolemia (p¼ 0.031) and had a ten-
dency for a higher body-mass-index (BMI) (p¼ 0.085).
They also showed a more frequent use of vasodilators
(p¼ 0.022) and lipid lowering agents (p¼ 0.045), re-
spectively statins, and a trend towards increased use
of beta-blockers (p¼ 0.082). Patients with and without
restenosis showed no difference in gender, age or risk
factors. Also the baseline levels of fibrinogen
(p¼ 0.243) and C-reactive-protein (CRP) (p¼ 0.424)
showed no impact on restenosis. Patientswho required
secondary stent implantation were significantly youn-
ger (p¼ 0.019).
Correlating each risk factor to the mean TGFb level
showed a borderline correlation between hypercho-
lesterolemia and TGFb (p¼ 0.056, r¼ 0.341). All other
risk factors revealed no significant correlation to TGFb
levels.
Soluble bFGF was detected in 16 patients (50%). In
16 patients (50%) the serum levels were below the de-
tection limit. The levels were 6.17 7.49 pg/ml before
intervention, 5.95 7.87 pg/ml at 15 minutes, 5.55
7.01 pg/ml at 60 minutes, 6.40 9.59 pg/ml at 24
hours, 6.18 9.01 pg/ml at 2 weeks and 6.29 7.58
pg/ml at four weeks in all patients. There was no sig-
nificant difference concerning either the intervention
type or an impact on restenosis development.
Soluble TNFa was detected in 19 patients (59%). In
13 patients (41%) the serum levels were below the
detection limit. Serum concentrations of TNFa were
1.18 1.47 pg/ml before the procedure, 1.39 1.34
pg/ml at 15 minutes, 1.34 1.39 pg/ml at 60 minutes,
1.44 1.44 pg/ml at 24 hours, 1.23 1.41 pg/ml at
2 weeks and 1.18 1.43 pg/ml at 4 weeks in all
patients. No significant difference for intervention
type or an impact on restenosis was found.
TGFb-1 was detected in all 32 patients. Table 5
shows the measured values of TGFb-1. Graph 1 shows
the course of TGFb-1 levels compared betweenTable 4. Procedural characteristics
Balloon n¼ 22 Stenting n¼ 10 Total n¼ 32 P Value
Used contrast material (in ml)y 190 64.1 164.5 80.6 182 68.3 0.344x
Residual stenosis after angioplasty (in %)y 14.55 11.43 2.0 4.22 10.63 11.16 0.003x
Treatment of more than 1 stenosis in the same artery* 2(9.1) 0(0) 2(4.5) 0.721z
Complication requirering surgical internvetion* 1(4.5) 0(0) 1(2.3) 0.494z
Run of vessels after intervention* 0.504z
3 run-off vessels 13(59.1) 5(50) 18(56.3)
2 run-off vessels 7(31.8) 5(50) 12(37.5)
1 run of vessel 2(9.1) 0(0) 2(6.2)
Restenosis after 6 months* 5(22.7) 5(50) 10(31.3) 0.217z
* Data are numbers of patients unless otherwise indicated, number in parentheses are percentages within group.
y Data are mean SD.
z P Value obtained with Fisher’s Exact Test.
x P Value obtained with Student’s t-Test.
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40 M. Wildgruber et al.Table 5. Soluble TGFb-1 in 32 patients with PAOD before and after interventional procedure
TGFb1 in ng/ml Balloon (n¼ 22) Stent (n¼ 10) No restenosis (n¼ 22) Restenosis (n¼ 10)
Before intervention 2.72 2.49 (0.06e8.31) 3.45 1.70 (0.10e6.04) 2.61 2.19 (0.06e8.31) 3.68 2.35 (0.08e7.04)
15 minutes 2.63 3.12 (0.07e11.20) 2.46 1.85 (0.30e7.13) 1.83 1.89 (0.07e7.44) 4.22 3.61 (0.30e11.20)
60 minutes 2.22 4.06 (0.01e19.70) 1.28 1.72 (0.05e6.26) 1.99 4.09 (0.01e19.70) 1.80 1.74 (0.09e5.02)
24 hours 3.04 3.33 (0.08e12.70) 5.71 4.89 (0.16e15.10) 2.90 3.19 (0.11e12.70) 6.04 4.92 (0.08e15.10)
2 weeks 3.47 3.63 (0.01e14.90) 3.81 3.87 (0.01e12.00) 2.69 2.87 (0.01e9.98) 5.52 4.53 (0.05e14.90)
4 weeks 3.24 2.50 (0.11e8.88) 3.88 1.99 (0.07e7.08) 3.18 2.36 (0.07e8.89) 4.03 2.30 (0.11e8.17)
Anova p< 0.001y p< 0.001y p< 0.01y p< 0.01y
Data are give as mean SD, number in parenthesis indicate range of values.
Significant changes in the time course of TGFb1 levels were observed in all groups.
Anova ¼ Analysis of variance
y Statistically significant.balloon and stent angioplasty. Graph 2 shows the
course of TGFb-1 levels between the restenosis and
non-restenosis group. TGFb-1 levels were in the ex-
pected range as provided by the manufacturer as
well as reported in the literature.
The baseline levels of TGFb-1 before the interven-
tional procedure did not differ significantly in patients
receiving balloon only or stent angioplasty (p¼ 0.327),
although the patients receiving stent implantation
showed higher values. In the time range of 15 and 60
minutes after the interventional procedure the levels
of TGFb-1 decreased almost uniformly in both the pa-
tients receiving balloon and stent angioplasty. 24 hours
after the procedure the values of the patients being
treated with balloon angioplasty had returned to base-
line levels. In those patients who received stent pros-
thesis the TGFb-1 levels 24 hours post stenting were
elevated compared to the patients who where treated
with PTA (p¼ 0.012). The increase of TGFb-1 levels
in the stent group at 24 hours was significant as com-
pared to the values at 60 minutes after the procedure
(p¼ 0.021), as well as compared to the baseline levels
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Graph 1. Course of TGFb-1 levels in patients with balloon
angioplasty and stent angioplasty.
Data shown are mean levels standard error of TGFb-1 at
the time on the day before intervention (0), 15 (1) and 60
(2) minutes after angioplasty, 24 hours after the intervention
(3), 2 (4) and 4 (5) weeks after the intervention. TGFb-1
levels were significantly higher in patients receiving stent
prosthesis at 24 hours compared to patients treated only
with balloon angioplasty (p¼ 0.012).
Eur J Vasc Endovasc Surg Vol 34, July 2007(p¼ 0.047). A level similar to those of the patients
treated with balloon angioplasty was reached at
2 weeks post procedure. Considering restenosis,
TGFb-1 levels did not differ significantly before the
intervention between patients who later developed
restenosis and those who did not (p¼ 0.238). After
the procedure however, TGFb-1 levels were signifi-
cantly higher in patients who later developed resteno-
sis compared to those who did not at 15 minutes
(p¼ 0.024), at 24 hours (p¼ 0.046) and at 2 weeks
(p¼ 0.047) post procedure. The increase of TGFb-1
levels in the restenosis group between 60 minutes
and 24 hours was significant (p¼ 0.032), while it was
not significant in the non-restnosis group (p¼ 0.114).
At 4 weeks the values of patients with and without
restenosis both fell to levels close to their baseline
values (p¼ 0.407 and p¼ 0.182) and the levels did
not differ significantly between the two groups
(p¼ 0.364). Comparing the values at 4 weeks
with the baseline levels, there were no significant
differences (balloon angioplasty: p¼ 0.113, stenting:
p¼ 0.556).
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Graph 2. Course of TGFb-1 levels in patients with restenosis
and without restenosis.
Data shown are mean levels standard error of TGFb-1 at
the time on the day before intervention (0), 15 (1) and 60
(2) minutes after the last angioplasty, 24 hours after the
intervention (3), 2 (4) and 4 (5) weeks after the intervention.
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In the cascade of restenosis formation growth factors
and cytokines such as bFGF, TNFa and TGFb-1 seem
toplayan important role9,17,25 and regulating thesepath-
ways may lead to new therapeutical approaches.4,18,26
Presently, little is known about the levels of these
factors, their possible impact on endothelial dysfunc-
tion and the rate of restenosis after angioplasty in
human arteries.
The aim of our study was to find a possible associ-
ation between circulating growth factors in the early
course after PTA and restenosis development.
Although increased expression after balloon
induced injury of both bFGF and TNFa were detected
in multiple tissue specimens of animal vessels,6,9,10,15
we did not find significant shifts in the serum levels
of these markers. In 16 patients regarding bFGF and
in 13 patients regarding TNFa the measured serum
levels were below the detection limit of the ELISA
reader at all 6 time points. In the remaining 16 respec-
tively 19 patients the levels did not exceed signifi-
cantly the minimum detection levels as provided by
the ELISA manufacturer. The extent of local damage
to the vessel wall induced by the angioplasty proce-
dure may be too weak to induce a detectable differ-
ence in the blood levels of these factors. This
observation is in accordance with other serologic
studies that did not detect TNFa changes in human
PAOD.27 An increase of soluble bFGF was found in
patients with stable angina after percutaneous trans-
luminal coronary angioplasty (PTCA).28 The absence
of bFGF after PTA in PAOD may be due to the minor
capacity of endothelial cells and medial SMCs to
release bFGF compared to ischemic myocardial cells
which are able to secret large amounts of bFGF to
promote collateral vessel growth in the ischemic
myocardium.
In our study the baseline levels of TGFb-1 were
higher in those patients who later developed resteno-
sis and in patients who required stent implantation. In
contrast to the ‘‘Just stent it’’ approach to the coronar-
ies, stenting in the peripheral circulation is performed
when balloon angioplasty itself is insufficient or the
morphological presentation of the lesion requires
a stent prosthesis. In our study, secondary stenting
was performed in case of arterial dissection, intimal
flap or a residual stenosis higher than 30%. To make
sure that the higher TGFb-1 levels obtained in the
patients with restenosis were not secondary to the
fact that they received a stent we tested for differences
in the restenosis group between patients being treated
with balloon and patients treated with stent angio-
plasty. Concerning restenosis there was no significantdifference between patients being treated with
balloon and patients treated with stent angioplasty
across the observed period (p> 0.05). The levels of
TGFb-1 dropped in patients without restenosis in
the time interval of 15 and 60 minutes after the proce-
dure while in patients with restenosis the TGFb-1
levels dropped at 60 minutes after the procedure
only. The reason for this discrepancy is not clear. An
initial decrease of serum concentrations was found
also in a study by Tsakiris who assessed levels of
circulating cell adhesion molecules in humans after
angioplasty in the lower limbs.29 This initial decrease
may be attributed to the effect of the non-ionic high
osmolar radiographic contrast material which was
used in all the procedures. Similar interactions
between soluble cytokines and immune reactions in
the ELISA have been observed in other studies.30 A
possible and even higher early increase of serum
concentration of growth factors may be masked by
this interference.
24 hours after the onset of injury the TGFb-1 levels
increased significantly in patients who received a stent
prosthesis but only moderately and not significantly
in patients treated with a balloon. This indicates that
not only the damage of the vessel wall caused by
the angioplasty-induced shear stress and circumferen-
tial wall stress is responsible for the inflammatory
reaction and growth stimulation, but also the implan-
tation of foreign material contributes to the arterial
remodelling. A severe TGFb-1 reaction in regions
adjacent to the implanted stent was seen in a porcine
model,31 however, comparative studies between
stenting and balloon angioplasty considering TGFb-1
reactions are still missing.
Patients developing restenosis had significantly
elevated serum levels of TGFb-1 at 15 minutes,
24 hours and at 2 weeks after angioplasty. This sug-
gests a possible contribution of TGFb-1 in the process
of restenosis. Majesky reported that expression of
TGFb-1 in the rat carotid is already significantly in-
creased 6 hours after the onset of injury and reaches
a maximum after 24 hours.15 Roller found elevated
serum levels of TGFb-1 48 hours after peripheral angio-
plasty but could not find a correlation between elevated
TGFb-1 levels and restenosis development.32 This
might be due to continued treatment with heparin
24 and 48 hours after the interventional procedure not
performed in our study. These data and our results
suggest that a possible contribution of TGFb-1 to reste-
nosis formation occurs most likely within the first two
weeks after the initial arterial trauma. The fact that pa-
tients who later develop restenosis show a higher risk
profile of hypercholesterolemia together with a more
frequent use of vasodilators, statins and beta-blockers,
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development. Correlating the risk factors to the mean
TGFb levels revealed a borderline significant correla-
tion of hypercholesterolemia with elevated TGFb
levels. It may be possible and cannot be excluded that
the higher TGFb-1 levels in the restenosis group are
influencedbyelevated lipid concentrations in the blood
and derive from a more severe pathology of vascular
disease and a higher degree of vessel inflammation.
Still, this may pose these patients at a higher risk for
restenotic events and TGFb-1 may been seen as a possi-
blemarker of the degree of vessel inflammation and the
associated risk for restenosis.
Although we found no significant difference in
TGFb-1 levels in the restenosis group between pa-
tients treated with stent or with balloon angioplasty,
this might be due to the small sample size. Further
investigations in a larger patient populations would
be helpful to clarify if elevated TGFb-1 levels in pa-
tients with restenosis result from stent implantation.
A second limitation is the fact that heparin influences
the binding kinetics of TGFb-1.33 Since both the TGFb-1
levels at 15 and 60 minutes after intervention may be
influenced by the heparin administration, these results
have to be interpreted with caution. Besides heparin,
several binding proteins such as 2aM and proteogly-
cans are effective in binding TGFb-1.21 Although these
effects are reduced by extraction procedures we cannot
rule out possible interferences of binding proteins with
the measured TGFb-1 levels.
The high standard deviation of the serum con-
centrations measured by ELISA derive from a high
range of the concentration levels. This is a well known
weakness of the ELISA method and is observed in
similar studies.29
In conclusion, this study shows that patients
who later developed restenosis show higher levels of
TGFb-1 at 15 minutes, 24 hours and 2 weeks after in-
tervention. The fact that the TGFb-1 levels had returned
to baseline levels after 4 weeks suggests that a possible
contribution of TGFb-1 to the initiation of restenosis
formation occurs in an early period after percutaneous
intervention.
Acknowledgements
The authors would like to thank Felicitas Altmayr (Depart-
ment of Surgery, Technical University of Munich) for her
technical support, Bernhard Holzmann (Department for
Surgery, Technical University of Munich) for providing the
laboratory setting as well as Raymonde Busch (Institute
for Medical Statistics and Epidemiology, Technical Univer-
sity of Munich) and Werner Lutzenberger, Ph.D. (University
of Tu¨bingen, Germany) for their statistical advise.
Eur J Vasc Endovasc Surg Vol 34, July 2007References
1 WYTTENBACH R, GALLINO A, ALERCI M, MAHLER F, COZZI L,
DI VALENTINO M et al. Effects of percutaneous transluminal
angioplasty and endovascular brachytherapy on vascular
remodeling of human femoropopliteal artery by noninvasive
magnetic resonance imaging. Circulation 2004;110:1156e1161.
2 CHENG SW, TING AC, WONG J. Endovascular stenting of super-
ficial femoral artery stenosis and occlusions: results and risk
factor analysis. Cardiovasc Surg 2001;9:133e140.
3 SCHWARTZ RS, TOPOL EJ, SERRUYS PW, SANGIORGI G, HOLMES Jr DR.
Artery size, neointima, and remodeling: time for some stan-
dards. J Am Coll Cardiol 1998;32:2087e2094.
4 RYAN ST, KOTELIANSKY VE, GOTWALS PJ, LINDNER V. Transforming
growth factor-beta-dependent events in vascular remodeling
following arterial injury. J Vasc Res 2003;40:37e46.
5 SINHA S, HEAGERTYAM, SHUTTLEWORTH CA, KIELTY CM. Expression
of latent TGF-beta binding proteins and association with
TGF-beta 1 and fibrillin-1 following arterial injury. Cardiovasc
Res 2002;53:971e983.
6 TANAKA H, SUKHOVA G, SCHWARTZ D, LIBBY P. Proliferating arterial
smooth muscle cells after balloon injury express TNF-alpha but
not interleukin-1 or basic fibroblast growth factor. Arterioscler
Thromb Vasc Biol 1996;16:12e18.
7 POTKIN BN, KEREN G, MINTZ GS, DOUEK PC, PICHARD AD,
SATLER LF et al. Arterial responses to balloon coronary angio-
plasty: an intravascular ultrasound study. J Am Coll Cardiol
1992;20:942e951.
8 SANGIORGI G, TAYLOR AJ, FARB A, CARTER AJ, EDWARDS WD,
HOLMES DR et al. Histopathology of postpercutaneous translumi-
nal coronary angioplasty remodeling in human coronary ar-
teries. Am Heart J 1999;138:681e687.
9 JOVINGE S, HULTGARDH-NILSSON A, REGNSTROM J, NILSSON J. Tumor
necrosis factor-alpha activates smooth muscle cell migration in
culture and is expressed in the balloon-injured rat aorta. Arterios-
cler Thromb Vasc Biol 1997;17:490e497.
10 MISIAKOS EP, KOURAKLIS G, AGAPITOS E, PERREA D, KARATZAS G,
BOUDOULAS H et al. Expression of PDGF-A, TGFb and VCAM-1
during the developmental stages of experimental atherosclero-
sis. Eur Surg Res 2001;33:264e269.
11 NESCHIS DG, SAFFORD SD, HANNA AK, FOX JC, GOLDEN MA.
Antisense basic fibroblast growth factor gene transfer reduces
early intimal thickening in a rabbit femoral artery balloon injury
model. J Vasc Surg 1998;27:126e134.
12 NIEMANN-JONSSON A, ARES MP, YAN ZQ, BU DX, FREDRIKSON GN,
BRANEN L et al. Increased rate of apoptosis in intimal arterial
smooth muscle cells through endogenous activation of TNF re-
ceptors. Arterioscler Thromb Vasc Biol 2001;21:1909e1914.
13 OTSUKA G, AGAH R, FRUTKIN AD, WIGHT TN, DICHEK DA. Trans-
forming growth factor beta 1 induces neointima formation
through plasminogen activator inhibitor-1-dependent pathways.
Arterioscler Thromb Vasc Biol 2006;26:737e743.
14 SHI Y, O’BRIEN Jr JE, FARD A, ZALEWSKI A. Transforming growth
factor-beta 1 expression and myofibroblast formation during
arterial repair. Arterioscler Thromb Vasc Biol 1996;16:1298e1305.
15 MAJESKY MW, LINDNER V, TWARDZIK DR, SCHWARTZ SM, REIDY MA.
Production of transforming growth factor beta 1 during repair of
arterial injury. J Clin Invest 1991;88:904e910.
16 WARNER SJ, LIBBY P.Humanvascular smoothmuscle cells. Target for
and source of tumor necrosis factor. J Immunol 1989;142:100e109.
17 LINDNER V, LAPPI DA, BAIRD A, MAJACK RA, REIDY MA. Role of
basic fibroblast growth factor in vascular lesion formation. Circ
Res 1991;68:106e113.
18 LINDNER V, REIDY MA. Proliferation of smooth muscle cells af-
ter vascular injury is inhibited by an antibody against basic
fibroblast growth factor. Proc Natl Acad Sci USA 1991;88:
3739e3743.
19 STONE GW, ARONOW HD. Long-term care after percutaneous
coronary intervention: focus on the role of antiplatelet therapy.
Mayo Clin Proc 2006;81:641e652.
43Course of Growth Factors in Restenosis after PTA20 STRECKER EP, BOOS IB, GOTTMANN D, VETTER S. Clopidogrel plus
long-term aspirin after femoro-popliteal stenting. The CLAFS
project: 1- and 2-year results. Eur Radiol 2004;14:302e308.
21 KROPF J, SCHUREK JO, WOLLNER A, GRESSNER AM. Immunological
measurement of transforming growth factor-beta 1 (TGF-beta1)
in blood; assay development and comparison. Clin Chem 1997;
43:1965e1974.
22 JAGER KA, PHILLIPS DJ, MARTIN RL, HANSON C, ROEDERER GO,
LANGLOIS YE et al. Noninvasive mapping of lower limb arterial
lesions. Ultrasound Med Biol 1985;11:515e521.
23 MONETA GL, YEAGER RA, ANTONOVIC R, HALL LD, CASTER JD,
CUMMINGS CA et al. Accuracy of lower extremity arterial duplex
mapping. J Vasc Surg 1992;15:275e283.
24 NEUERBURG-HEUSLER D, KARASCH T. Determining the degree of
stenosis of peripheral arteries. Hemodynamic and ultrasound
principles. Vasa 1996;25:109e113.
25 NIKOL S, ISNER JM, PICKERING JG, KEARNEY M, LECLERC G, WEIR L.
Expression of transforming growth factor-beta 1 is increased in
human vascular restenosis lesions. J Clin Invest 1992;90:
1582e1592.
26 GENG YJ, WU Q, MUSZYNSKI M, HANSSON GK, LIBBY P. Apoptosis
of vascular smooth muscle cells induced by in vitro stimula-
tion with interferon-gamma, tumor necrosis factor-alpha, and
interleukin-1 beta. Arterioscler Thromb Vasc Biol 1996;16:
19e27.
27 DANIELSSON P, SCHATZ P, SWARTBOL P, TRUEDSSON L, DANIELSSON G,
ZDANOWSKI Z et al. Response of inflammatory markers to balloonangioplasty in peripheral arterial occlusive disease. Eur J Vasc
Endovasc Surg 2000;20:550e555.
28 KATINIOTI AA, TOUSOULIS D, ECONOMOU E, STEFANADIS C, TRIKAS A,
TENTOLOURIS C et al. Basic fibroblast growth factor changes in re-
sponse to coronary angioplasty in patients with stable angina.
Int J Cardiol 2002;84:195e199.
29 TSAKIRIS DA, TSCHOPL M, JAGER K, HAEFELI WE, WOLF F,
MARBET GA. Circulating cell adhesion molecules and endothelial
markers before and after transluminal angioplasty in peripheral
arterial occlusive disease. Atherosclerosis 1999;142:193e200.
30 BOHM I, SPECKU, SCHILDH.Cytokineprofiles after nonionicdimeric
contrast medium injection. Invest Radiol 2003;38:776e783.
31 WARD MR, AGROTIS A, KANELLAKIS P, HALL J, JENNINGS G, BOBIK A.
Tranilast prevents activation of transforming growth factor-beta
system, leukocyte accumulation, and neointimal growth in
porcine coronary arteries after stenting. Arterioscler Thromb
Vasc Biol 2002;22:940e948.
32 ROLLER RE, OBERNOSTERER A, DORR A, SCHNEDLWJ. No association
of TGF-beta1 antigen with the development of restenosis in
patients undergoing peripheral angioplasty. Thromb Haemost
2000;84:518e519.
33 RIDER CC. Heparin/heparan sulphate binding in the TGF-beta
cytokine superfamily. Biochem Soc Trans 2006;34:458e460.
Accepted 15 February 2007
Available online 2 May 2007Eur J Vasc Endovasc Surg Vol 34, July 2007
